HIV/AIDS – Medxy AI

Scaling Tobacco Cessation in HIV Care: National Quitlines as an Effective Alternative to Resource-Intensive Interventions

By MedXY 02/24/2026

A landmark pragmatic randomized controlled trial in Vietnam reveals that proactive Quitline referrals are as effective as nurse-led counseling and nicotine replacement therapy for smoking cessation among people living with HIV, offering a scalable model for low- and middle-income countries.

Infectious Diseases news

Long-Acting Injectable ART Superior to Oral Regimens in Patients with HIV Adherence Challenges: Insights from the LATITUDE Trial

By MedXY 02/22/2026

The LATITUDE trial reveals that monthly injectable cabotegravir-rilpivirine significantly reduces treatment failure compared to standard oral ART in individuals with HIV who struggle with daily medication adherence, potentially reshaping clinical guidelines for vulnerable patient populations.

news

Optimizing Cervical Cancer Screening for Women Living with HIV: New Data Supports Starting at Age 25

By MedXY 02/19/2026

A large-scale meta-analysis reveals age-specific risks for cervical precancer in women living with HIV, justifying the WHO recommendation to initiate screening at age 25 with 3–5 year intervals to mitigate high recurrence and progression rates.

news Public Health

Substantial HIV Burden and Critical Gaps in the Care Cascade Among Men Who Have Sex With Men in Iran

By MedXY 02/19/2026

A nationwide biobehavioural survey in Iran reveals a 4.2% HIV prevalence among MSM, highlighting significant disparities in viral suppression despite moderate linkage to care, emphasizing the need for targeted, stigma-free interventions.

news Pediatrics

Beyond the Daily Pill: The Dawn of Long-Acting HIV Treatment for Adolescents

By MedXY 02/19/2026

The IMPAACT 2017/MOCHA study reveals that long-acting injectable cabotegravir and rilpivirine administered every eight weeks is safe and highly effective for adolescents with HIV, potentially transforming the landscape of pediatric HIV care and adherence.

news Pediatrics

Targeted Bone Support: High-Dose Vitamin D and Calcium Improve Bone Mineral Density in Adolescents with HIV and Baseline Insufficiency

By MedXY 01/14/2026

The VITALITY trial reveals that while high-dose vitamin D and calcium supplementation did not benefit all adolescents with HIV, it significantly improved bone density in those with baseline vitamin D insufficiency, providing a safe strategy for optimizing peak bone mass.